nivolumab,ipilimumab,cabozantinib
bms
['nivolumab', 'rcc,(-irccs),(-srcc),(-urcc)', 'cabozantinib', ' ipi ', 'ipilimumab', 'cabo ', 'nivo', 'cosmic-313']
conference by powles md showing us the cosmic-313study, c+n+i improved pfs vs p+n+i in first-line arcc of imdc intermediate or poor risk; subgroup analysis suggested that the benefit was primarily in intermediate risk pts and comment that follow-up for os is ongoing #ascogu2023 
Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla. Cancer treatment must be personalized to the individual needs of the patient.